Vision2Voice
2 Experiments Proving Pharma Education Matters
In the last 25 years, two events have changed the face of how we educate doctors. The first occurred in 1992 when Merck introduced a revolutionary new product for benign prostatic hyperplasia (BPH)—PROSCAR (finasteride). It was hailed as so revolutionary that Merck’s CEO, P. Roy Vagelos, MD, hypothesized that doctors Read more…
